Patent Number: 7,132,537

Title: Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states

Abstract: This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.

Inventors: Wells; Ibert Clifton (Omaha, NE)

Assignee: Magnesium Diagnostics, Inc.

International Classification: C07D 239/02 (20060101); A61K 31/505 (20060101); A61K 31/47 (20060101); C07D 215/00 (20060101)

Expiration Date: 2019-11-07 0:00:00